Revenue Surge: Recent discussions on social media have been buzzing about ImmunityBio's staggering 700% revenue increase for 2025, largely driven by the success of their cancer therapy, Anktiva. Many users are highlighting the company's reported $113 million in preliminary net product revenue as a sign of strong commercial performance. This news has sparked a flurry of excitement and optimism among followers.
Regulatory Approvals: Another hot topic is the recent approval of Anktiva by Saudi regulators for lung and bladder cancer treatments, following nods from the U.S. and other regions. Social media conversations are focusing on how this expands the drug's market potential, with some calling it a game-changer for the biotech firm. The chatter reflects a sense of anticipation for further global traction.
Stock Movement: The stock's significant price jump, with reports of a 28% surge in a short period, is also fueling discussions online. Some participants are speculating about large trades and insider knowledge, adding an air of intrigue to the conversation. The momentum continues to draw attention as new clinical program updates emerge.
Note: This discussion summary was generated from an AI condensation of post data.
ImmunityBio Hedge Fund Activity
We have seen 145 institutional investors add shares of ImmunityBio stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 7,764,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $19,099,440
- BANK OF AMERICA CORP /DE/ removed 7,101,407 shares (-81.1%) from their portfolio in Q3 2025, for an estimated $17,469,461
- HEIGHTS CAPITAL MANAGEMENT, INC added 6,565,709 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,151,644
- VANGUARD GROUP INC added 5,837,898 shares (+26.8%) to their portfolio in Q3 2025, for an estimated $14,361,229
- JANE STREET GROUP, LLC added 5,117,314 shares (+66.3%) to their portfolio in Q3 2025, for an estimated $12,588,592
- STATE STREET CORP added 3,700,247 shares (+48.6%) to their portfolio in Q3 2025, for an estimated $9,102,607
- MILLENNIUM MANAGEMENT LLC removed 3,195,410 shares (-98.5%) from their portfolio in Q3 2025, for an estimated $7,860,708
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ImmunityBio Analyst Ratings
Wall Street analysts have issued reports on $IBRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 01/13/2026
- HC Wainwright & Co. issued a "Buy" rating on 09/10/2025
To track analyst ratings and price targets for ImmunityBio, check out Quiver Quantitative's $IBRX forecast page.
ImmunityBio Price Targets
Multiple analysts have issued price targets for $IBRX recently. We have seen 3 analysts offer price targets for $IBRX in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $24.0 on 01/16/2026
- Kelly Shi from Jefferies set a target price of $9.0 on 12/12/2025
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $8.0 on 09/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
